Evidence map›Paper›PMID 34221910›Full record

ArticleMethodsX2021

High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.

Richard B M Schasfoort, Jos van Weperen, Margot van Amsterdam, Judicaël Parisot, Jan Hendriks, Michelle Koerselman, Marcel Karperien, Anouk Mentink, Martin Bennink, Hans Krabbe and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MethodsX, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Richard B M SchasfoortDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
Jos van WeperenVysens BV, PO Box 50035, 7550 LA Hengelo, The Netherlands.
Margot van AmsterdamDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
Judicaël ParisotCarterra, 825 N. 300 W., Suite C309, Salt Lake City, UT 84103, USA.
Jan HendriksDepartment of Developmental BioEngineering, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
Michelle KoerselmanDepartment of Developmental BioEngineering, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
Marcel KarperienDepartment of Developmental BioEngineering, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
Anouk MentinkDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
Martin BenninkNanoBio research group, Saxion University of Applied Sciences, PO Box 70000, 7500 KB Enschede, The Netherlands.
Hans KrabbeDepartment of Clinical Chemistry and Laboratory Medicine, Medisch Spectrum Twente, PO Box 50000. 7500 KA Enschede, The Netherlands.
Leon Wmm TerstappenDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
A H Leontine MulderDepartment of Clinical Chemistry, Medlon BV, 7512 KZ Enschede, The Netherlands.
University of Twente · NLCarterra (United States) · USMedisch Spectrum Twente · NLSaxion University of Applied Sciences · NLZiekenhuis Groep Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 102 CoViD-19 and non-CoViD-19 patients. The SPRi assay simultaneously measures the antibody isotype levels and the strength of binding to the RBD of ultimate 384 patient samples in one run. It turns out that during the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels go down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The anti-RBD immunoglobulins SPRi assay provides additional insights in the immune status of patients recovering from CoViD-19. This new high throughput method can be applied for the assessment of the quality of the immune reaction of healthy individuals to SARS-CoV-2 and its mutants in vaccination programs.•Surface Plasmon Resonance imaging is an unprecedented technology for high throughput screening of antibody profiling of CoViD19 patients.•Fingerprinting of isotypes IgM, IgG and IgA can be performed for 384 patients in one run.•An affinity maturation effect was shown for patients recovering from CoViD19.

Indexed as

AffinityAntibody isotypesBiosensorCoronaHigh throughputInfectious diseasesOff-rate

Identifiers

PMID34221910
PMCPMC8239317
OpenAlexW3176509967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.